Navigation Links
YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference
Date:10/1/2010

inistered inhibitor of both the JAK1 and JAK2 kinase enzymes, which have been implicated in a number of immune cell disorders including myeloproliferative disorders and inflammatory diseases as well as certain cancers. CYT387 is currently in a Phase I/II trial in myelofibrosis with detailed initial safety and activity data expected at the American Society of Hematology (ASH) meeting in December 2010. Nimotuzumab is a humanized monoclonal antibody targeting EGFR with a potential best-in-class side effect profile. Nimotuzumab is being evaluated in numerous Phase II and III trials worldwide by YM's licensees. CYT997 is a uniquely orally-available agent with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension
2. YM BioSciences reports fiscal year end 2010 operational and financial results
3. Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City
4. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
5. Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
6. Signum Biosciences Names Braham Shroot as Chief Executive Officer
7. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
8. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
9. Ambit Biosciences Announces Transition in Company Leadership
10. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
11. Calithera Biosciences Closes $40 Million in Series A Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Quorum Review IRB, the industry leader in central IRB ... Quick Step™ . The offering went live on July ... need for seamless study start-up with a large volume of ... 50 or more North American investigator sites, as well as ... of 80 or more. Qualifying studies may also enroll international ...
(Date:7/22/2014)... Los Angeles, CA (PRWEB) July 22, 2014 ... rapid test solutions with the debut of its ... Association of Clinical Chemistry (AACC) meeting in Chicago, ... based or bench top versions, the HRDR-300 is ... patent pending technology to analyze fluorescent lateral flow ...
(Date:7/22/2014)... Lawrence, KS (PRWEB) July 22, 2014 ... as attention-deficit hyperactivity disorder (ADHD) is diagnosed, selecting medication ... trial and error. Analyzing brain patterns by using electroencephalography ... best result and thus lower the risk of adverse ... Electroencephalography Phenotypes and Biomarkers” in the current issue ...
(Date:7/22/2014)... Greenville, SC (PRWEB) July 22, 2014 ... chorus of those who have recognized that the greatest ... inefficient, and far too often needlessly deadly while trying ... the multitude of quasi-experts seeking to transform an enormous ... detail.” , Dr. Williams, in his continuing series of ...
Breaking Biology Technology:Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 2Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials 3Holomic to Debut HRDR-300 Fluorescent Immunoassay Reader at the AACC 2014 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 3Dr. Ira Williams Asks What’s Wrong With Jonathan Bush’s Book, Where Does It Hurt? 2
... Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader ... President Deborah Jenkins Hutchinson, will present a corporate update ... June 23, 2011 at 10 am EDT  held at ... New York City. The presentation will be webcast live ...
... 2011 Five exceptional oncology nurses out of ... Solutions | US Oncology for their dedication ... Excellence in Oncology Nursing Award honors those nurses in the ... courage and determination in providing the highest quality oncology nursing ...
... BASEL, Switzerland, June 22, 2011 The Roche manuscript: ... Production of Bispecific IgG Antibodies" has been published in ... of the USA (PNAS). Corresponding authors are ... at Penzberg, and Christian Klein, Head of Oncology Programs, ...
Cached Biology Technology:Wound Management Technologies' Webcasting Live from OneMedForum NY Biotech Conference on Thursday, June 23 at 10 am EDT 2Wound Management Technologies' Webcasting Live from OneMedForum NY Biotech Conference on Thursday, June 23 at 10 am EDT 3McKesson Specialty Care Solutions | US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work 2McKesson Specialty Care Solutions | US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work 3McKesson Specialty Care Solutions | US Oncology Honors Five Exceptional Oncology Nurses for Outstanding Work 4Proceedings of the National Academy of Sciences (PNAS) Publishes Roche Manuscript on Production of Bispecific IgG Antibodies 2
(Date:7/22/2014)... 22, 2014 BGI Tech Solutions Co., LTD, ... largest genomics organization, announced today the global launch ... based on Complete Genomics, industry-leading platform. This newly ... validation, and is available at reduced prices until ... regarded in the industry for providing proprietary sequencing ...
(Date:7/22/2014)... BOSTON -- Open a child,s lunch box and you,re likely ... of federal guidelines. Those are the findings of a study ... and Policy at Tufts University and in the Department of ... Medicine. The findings are published online ahead of print ... Dietetics . , Led by senior author Jeanne Goldberg, ...
(Date:7/21/2014)... of a multinational, collaborative effort, researchers from Canada,s Centre ... over 100 locations in the human genome associated with ... largest genomic study published on any psychiatric disorder to ... point to biological mechanisms and pathways that may underlie ... the disorder, which has seen little innovation in drug ...
Breaking Biology News(10 mins):BGI Tech launches human whole exome sequencing service on complete genomics' advanced platform 2Room for improvement in elementary school children's lunches and snacks from home 2International team sheds new light on biology underlying schizophrenia 2International team sheds new light on biology underlying schizophrenia 3
... Partner -- CHANTILLY, Virginia, November 18, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... The most widely adopted measure for assessing the state of ... nearly half the ecosystems where it was applied according to ... of Washington fisheries scientist. "Applied to individual ecosystems it,s like ... answer and half the time you get the wrong answer," ...
... spring into action to begin repairing muscle damaged in a ... found that a protein naturally produced in the body may ... the right dose of this protein named secreted frizzled related ... heart failure and reduce collagen layering that can form thick ...
Cached Biology News:The CLEAR Program is Back and Oberthur Technologies Remains a Key Partner 2The CLEAR Program is Back and Oberthur Technologies Remains a Key Partner 3The CLEAR Program is Back and Oberthur Technologies Remains a Key Partner 4The CLEAR Program is Back and Oberthur Technologies Remains a Key Partner 5The CLEAR Program is Back and Oberthur Technologies Remains a Key Partner 6The CLEAR Program is Back and Oberthur Technologies Remains a Key Partner 7The CLEAR Program is Back and Oberthur Technologies Remains a Key Partner 8The CLEAR Program is Back and Oberthur Technologies Remains a Key Partner 9Scientists question indicator of fisheries health, evidence for 'fishing down food webs' 2Scientists question indicator of fisheries health, evidence for 'fishing down food webs' 3A stem cell secreted protein can be given to improve heart function after experimental heart attack 2
Applications: Epitope mapping, Mapping protein-protein contacts, Identification of enzyme substrates/inhibitors, Identification of receptor agonists/antagonists...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: